Summit Therapeutics Inc.
Summit Therapeutics Inc. (Nasdaq: SMMT) is a biopharmaceutical company focused on developing oncology therapies, with operations centered on clinical development of its lead candidate, ivonescimab. Ivonescimab is a bispecific antibody designed to block PD-1 and VEGF-A pathways in a single molecule. Summit is… From the company’s description.
In fiscal 2025, Summit Therapeutics Inc. reported a net loss of $1.08B. Operations used $322.93M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Summit Therapeutics Inc. does
In the company’s own words
Summit Therapeutics Inc. (Nasdaq: SMMT) is a biopharmaceutical company focused on developing oncology therapies, with operations centered on clinical development of its lead candidate, ivonescimab. Ivonescimab is a bispecific antibody designed to block PD-1 and VEGF-A pathways in a single molecule. Summit is conducting Phase III trials evaluating ivonescimab, alone or with chemotherapy, in non-small cell lung cancer and metastatic colorectal cancer; its lead program targets previously treated EGFR-mutated lung cancer, and the FDA accepted Summit’s application for that proposed use in January 2026. The company licensed rights from Akeso to develop and commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa, while Akeso retained rights elsewhere. Summit has no reportable business segments described in the provided business overview; its activities are focused on ivonescimab and related clinical development. Its website is www.smmttx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MIAMI, FL
- Fiscal year end
- December
- CIK
- 1599298
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Summit Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Summit Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Summit Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Summit Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Summit Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”